Expertise in
3
conditions

Heinz Laubli

Basel, BS, CH 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
3
conditions
Basel, BS, CH 

Overview

Heinz Laubli practices practicing medicine in Basel, Switzerland.

Mr. Laubli is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Melanoma, Glioblastoma, Astrocytoma, and Glioma.

He is actively involved in clinical research, co-authoring 129 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Basel, BS, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Enrollment Status: Recruiting
Publish Date: July 30, 2026
Intervention Type: Drug, Radiation, Biological
Study Drugs: Temozolomide, Lomustine, Regorafenib, Paxalisib, VAL-083
Study Phase: Phase 2/Phase 3
A Phase I Study of Adoptive Tumor-infiltrating Lymphocyte Transfer in Combination With Nivolumab in Patients With Advanced Melanoma
A Phase I Study of Adoptive Tumor-infiltrating Lymphocyte Transfer in Combination With Nivolumab in Patients With Advanced Melanoma
Enrollment Status: Completed
Publish Date: April 10, 2024
Intervention Type: Drug
Study Drug: Combination of Tumor Infiltrating Lymphocytes Transfer with anti-PD-1 Therapy and Low Dose IL-2
Study Phase: Phase 1
View 1 Less Clinical Trial

129 Total Publications

α2,3-sialylation on human naïve T cells restrains bispecific engager-mediated anti-tumor immunity.
α2,3-sialylation on human naïve T cells restrains bispecific engager-mediated anti-tumor immunity.
Journal: bioRxiv : the preprint server for biology
Published: August 20, 2026

Frequently Asked Questions about Heinz Laubli

Is Heinz Laubli a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Heinz Laubli is classified as an Advanced expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Heinz Laubli participate in research or clinical trials?

Yes. Heinz Laubli has published 129 articles and abstracts on conditions like Melanoma. You can view a list of Heinz Laubli's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Laubli's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile